ID   SP1_RAT                 Reviewed;         786 AA.
AC   Q01714; Q8K4R0;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 2.
DT   29-MAY-2024, entry version 188.
DE   RecName: Full=Transcription factor Sp1;
GN   Name=Sp1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=1356762; DOI=10.1002/j.1460-2075.1992.tb05451.x;
RA   Imataka H., Sogawa K., Yasumoto K., Kikuchi Y., Sasano K., Kobayashi A.,
RA   Hayami M., Fujii-Kuriyama Y.;
RT   "Two regulatory proteins that bind to the basic transcription element
RT   (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene.";
RL   EMBO J. 11:3663-3671(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-559, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=12379234; DOI=10.1016/s0006-291x(02)02419-1;
RA   Takahara T., Kasahara D., Mori D., Yanagisawa S., Akanuma H.;
RT   "The trans-spliced variants of Sp1 mRNA in rat.";
RL   Biochem. Biophys. Res. Commun. 298:156-162(2002).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH SMARCA4/BRG1.
RX   PubMed=19081374; DOI=10.1016/j.neuron.2008.09.040;
RA   Qiu Z., Ghosh A.;
RT   "A calcium-dependent switch in a CREST-BRG1 complex regulates activity-
RT   dependent gene expression.";
RL   Neuron 60:775-787(2008).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2 AND SER-7, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Transcription factor that can activate or repress
CC       transcription in response to physiological and pathological stimuli.
CC       Binds with high affinity to GC-rich motifs and regulates the expression
CC       of a large number of genes involved in a variety of processes such as
CC       cell growth, apoptosis, differentiation and immune responses. Highly
CC       regulated by post-translational modifications (phosphorylations,
CC       sumoylation, proteolytic cleavage, glycosylation and acetylation).
CC       Binds also the PDGFR-alpha G-box promoter. May have a role in
CC       modulating the cellular response to DNA damage. Implicated in chromatin
CC       remodeling. Plays an essential role in the regulation of FE65 gene
CC       expression. Positively regulates the transcription of the core clock
CC       component BMAL1 (By similarity). Plays a role in the recruitment of
CC       SMARCA4/BRG1 on the c-FOS promoter (PubMed:19081374). Plays a role in
CC       protecting cells against oxidative stress following brain injury by
CC       regulating the expression of RNF112 (By similarity).
CC       {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:P08047,
CC       ECO:0000269|PubMed:19081374}.
CC   -!- SUBUNIT: Interacts with ATF7IP, ATF7IP2, BAHD1, POGZ, HCFC1, AATF and
CC       PHC2. Interacts with SV40 VP2/3 proteins. Interacts with SV40 major
CC       capsid protein VP1; this interaction leads to a cooperativity between
CC       the 2 proteins in DNA binding. Interacts with HLTF; the interaction may
CC       be required for basal transcriptional activity of HLTF. Interacts
CC       (deacetylated form) with EP300; the interaction enhances gene
CC       expression. Interacts with HDAC1 and JUN. Interacts with ELF1; the
CC       interaction is inhibited by glycosylation of SP1. Interaction with
CC       NFYA; the interaction is inhibited by glycosylation of SP1 (By
CC       similarity). Interacts with SMARCA4/BRG1 (PubMed:19081374). Interacts
CC       with ATF7IP and TBP. Interacts with MEIS2 and PBX1. Interacts with
CC       EGR1. Interacts with RNF112 in an oxidative stress-regulated manner (By
CC       similarity). Interacts with ZBTB7A; ZBTB7A prevents the binding to GC-
CC       rich motifs in promoters and represses the transcriptional activity of
CC       SP1 (By similarity). Interacts with DDX3X; this interaction potentiates
CC       SP1-induced CDKN1A/WAF1/CIP1 transcription (By similarity). Interacts
CC       with MSX1; the interaction may inhibit MSX1 autoinactivation (By
CC       similarity). Interacts with MSX3 (By similarity).
CC       {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:P08047,
CC       ECO:0000269|PubMed:19081374}.
CC   -!- INTERACTION:
CC       Q01714; P18576: Nfya; NbExp=2; IntAct=EBI-862787, EBI-862695;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:O89090}. Cytoplasm
CC       {ECO:0000250}. Note=Nuclear location is governed by
CC       glycosylated/phosphorylated states. Insulin promotes nuclear location,
CC       while glucagon favors cytoplasmic location (By similarity).
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested, including lung,
CC       kidney, spleen and thymus. {ECO:0000269|PubMed:12379234}.
CC   -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000250|UniProtKB:P08047}.
CC   -!- PTM: Phosphorylated on multiple serine and threonine residues.
CC       Phosphorylation is coupled to ubiquitination, sumoylation and
CC       proteolytic processing. Phosphorylation on Ser-60 enhances proteolytic
CC       cleavage. Phosphorylation on Ser-7 enhances ubiquitination and protein
CC       degradation. Hyperphosphorylation on Ser-102 in response to DNA damage
CC       has no effect on transcriptional activity. MAPK1/MAPK3-mediated
CC       phosphorylation on Thr-454 and Thr-740 enhances VEGF transcription but,
CC       represses FGF2-triggered PDGFR-alpha transcription. Also implicated in
CC       the repression of RECK by ERBB2. Hyperphosphorylated on Thr-279 and
CC       Thr-740 during mitosis by MAPK8 shielding SP1 from degradation by the
CC       ubiquitin-dependent pathway. Phosphorylated in the zinc-finger domain
CC       by calmodulin-activated PKCzeta. Phosphorylation on Ser-642 by PKCzeta
CC       is critical for TSA-activated LHR gene expression through release of
CC       its repressor, p107. Phosphorylation on Thr-669, Ser-671 and Thr-682 is
CC       stimulated by angiotensin II via the AT1 receptor inducing increased
CC       binding to the PDGF-D promoter. This phosphorylation is increased in
CC       injured artey wall. Ser-60 and Thr-682 can both be dephosphorylated by
CC       PP2A during cell-cycle interphase. Dephosphorylation on Ser-60 leads to
CC       increased chromatin association during interphase and increases the
CC       transcriptional activity. On insulin stimulation, sequentially
CC       glycosylated and phosphorylated on several C-terminal serine and
CC       threonine residues (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Acetylation/deacetylation events affect
CC       transcriptional activity. Deacetylation leads to an increase in the
CC       expression the 12(s)-lipooxygenase gene though recruitment of p300 to
CC       the promoter (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Ubiquitination occurs on the C-terminal
CC       proteolytically-cleaved peptide and is triggered by phosphorylation (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylation modulates proteolytic cleavage
CC       of the N-terminal repressor domain. Sumoylation levels are attenuated
CC       during tumorigenesis. Phosphorylation mediates SP1 desumoylation (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Proteolytic cleavage in the N-terminal repressor domain is
CC       prevented by sumoylation. The C-terminal cleaved product is susceptible
CC       to degradation (By similarity). {ECO:0000250}.
CC   -!- PTM: O-glycosylated; Contains 8 N-acetylglucosamine side chains. Levels
CC       are controlled by insulin and the SP1 phosphorylation states. Insulin-
CC       mediated O-glycosylation locates SP1 to the nucleus, where it is
CC       sequentially deglycosylated and phosphorylated. O-glycosylation affects
CC       transcriptional activity through disrupting the interaction with a
CC       number of transcription factors including ELF1 and NFYA. Inhibited by
CC       peroxisomome proliferator receptor gamma (PPARgamma) (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the Sp1 C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D12768; BAA02235.1; -; mRNA.
DR   EMBL; AB077988; BAC05486.1; -; Genomic_DNA.
DR   PIR; JS0747; JS0747.
DR   RefSeq; NP_036787.2; NM_012655.2.
DR   AlphaFoldDB; Q01714; -.
DR   SMR; Q01714; -.
DR   BioGRID; 246914; 7.
DR   IntAct; Q01714; 2.
DR   MINT; Q01714; -.
DR   STRING; 10116.ENSRNOP00000019403; -.
DR   GlyCosmos; Q01714; 6 sites, No reported glycans.
DR   GlyGen; Q01714; 7 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; Q01714; -.
DR   PhosphoSitePlus; Q01714; -.
DR   PaxDb; 10116-ENSRNOP00000019403; -.
DR   Ensembl; ENSRNOT00000019403.7; ENSRNOP00000019403.5; ENSRNOG00000014084.7.
DR   Ensembl; ENSRNOT00055046909; ENSRNOP00055038532; ENSRNOG00055027129.
DR   Ensembl; ENSRNOT00060025416; ENSRNOP00060020260; ENSRNOG00060014868.
DR   Ensembl; ENSRNOT00065038163; ENSRNOP00065030898; ENSRNOG00065022366.
DR   GeneID; 24790; -.
DR   KEGG; rno:24790; -.
DR   UCSC; RGD:3738; rat.
DR   AGR; RGD:3738; -.
DR   CTD; 6667; -.
DR   RGD; 3738; Sp1.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000157804; -.
DR   HOGENOM; CLU_019688_2_0_1; -.
DR   InParanoid; Q01714; -.
DR   OMA; NWSFCGK; -.
DR   OrthoDB; 5396935at2759; -.
DR   PhylomeDB; Q01714; -.
DR   TreeFam; TF350150; -.
DR   Reactome; R-RNO-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-RNO-6807505; RNA polymerase II transcribes snRNA genes.
DR   Reactome; R-RNO-9762293; Regulation of CDH11 gene transcription.
DR   PRO; PR:Q01714; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000014084; Expressed in spleen and 19 other cell types or tissues.
DR   GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0000791; C:euchromatin; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:RGD.
DR   GO; GO:0017053; C:transcription repressor complex; ISO:RGD.
DR   GO; GO:0043425; F:bHLH transcription factor binding; ISO:RGD.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0060090; F:molecular adaptor activity; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0001221; F:transcription coregulator binding; IPI:ARUK-UCL.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1904568; P:cellular response to wortmannin; IEP:RGD.
DR   GO; GO:0034224; P:cellular response to zinc ion starvation; IEP:RGD.
DR   GO; GO:0060216; P:definitive hemopoiesis; ISO:RGD.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; ISO:RGD.
DR   GO; GO:0001892; P:embryonic placenta development; ISO:RGD.
DR   GO; GO:0060136; P:embryonic process involved in female pregnancy; ISO:RGD.
DR   GO; GO:0048706; P:embryonic skeletal system development; ISO:RGD.
DR   GO; GO:0043353; P:enucleate erythrocyte differentiation; ISO:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0001889; P:liver development; ISO:RGD.
DR   GO; GO:0030324; P:lung development; ISO:RGD.
DR   GO; GO:0030219; P:megakaryocyte differentiation; ISO:RGD.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; ISO:RGD.
DR   GO; GO:0001503; P:ossification; ISO:RGD.
DR   GO; GO:0043923; P:positive regulation by host of viral transcription; IEA:Ensembl.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; ISO:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISO:RGD.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:1904828; P:positive regulation of hydrogen sulfide biosynthetic process; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; ISO:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:RGD.
DR   GO; GO:0033194; P:response to hydroperoxide; ISS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0001829; P:trophectodermal cell differentiation; ISO:RGD.
DR   CDD; cd22539; SP1_N; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 3.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1.
DR   PANTHER; PTHR23235:SF16; TRANSCRIPTION FACTOR SP1; 1.
DR   Pfam; PF00096; zf-C2H2; 2.
DR   SMART; SM00355; ZnF_C2H2; 3.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Biological rhythms; Cytoplasm; DNA-binding;
KW   Glycoprotein; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   CHAIN           2..786
FT                   /note="Transcription factor Sp1"
FT                   /id="PRO_0000047139"
FT   ZN_FING         627..656
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         657..686
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         687..714
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..94
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..83
FT                   /note="Repressor domain"
FT                   /evidence="ECO:0000250"
FT   REGION          110..143
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          147..252
FT                   /note="Transactivation domain A (Gln-rich)"
FT                   /evidence="ECO:0000250"
FT   REGION          262..496
FT                   /note="Transactivation domain B (Gln-rich)"
FT                   /evidence="ECO:0000250"
FT   REGION          281..303
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          332..397
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          497..611
FT                   /note="Transactivation domain C (highly charged)"
FT                   /evidence="ECO:0000250"
FT   REGION          562..600
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          620..786
FT                   /note="VZV IE62-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          709..786
FT                   /note="Domain D"
FT                   /evidence="ECO:0000250"
FT   MOTIF           463..471
FT                   /note="9aaTAD"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   COMPBIAS        29..64
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        71..94
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            64..65
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         7
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         60
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         102
FT                   /note="Phosphoserine; by ATM"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         279
FT                   /note="Phosphothreonine; by MAPK8"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         454
FT                   /note="Phosphothreonine; by MAPK1 and MAPK3"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         613
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         641
FT                   /note="Phosphothreonine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         642
FT                   /note="Phosphoserine; by PKC/PRKCZ; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         652
FT                   /note="Phosphothreonine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         669
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         671
FT                   /note="Phosphoserine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         682
FT                   /note="Phosphothreonine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         699
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         703
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         704
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   MOD_RES         740
FT                   /note="Phosphothreonine; by MAPK1, MAPK3 and MAPK8"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   CARBOHYD        492
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        613
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        641
FT                   /note="O-linked (GlcNAc) threonine; alternate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        642
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        699
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        703
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        15
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        15
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08047"
FT   CONFLICT        78
FT                   /note="N -> NEN (in Ref. 1; BAA02235)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   786 AA;  80772 MW;  3DE2AD93F95E7C0B CRC64;
     MSDQDHSMDE VTAVKIEKGV GGNNGGSGNG GGAAFSQTRS SSTGSSSSSG GGGGQESQPS
     PLALLAATCS RIESPNENSN NSQGPSQSGG TGELDLTATQ LSQGANGWQI ISSSSGATPT
     SKEQSGNSTN GSNGSESSKN RTVSGGQYVV AATPNLQNQQ VLTGLPGVMP NIQYQVIPQF
     QTVDGQQLQF AATGAQVQQD GSGQIQIIPG ANQQIITNRG SGGNIIAAMP NLLQQAVPLQ
     GLANNVLSGQ TQYVTNVPVA LNGNITLLPV NSVSAATLTP SSQAGTISSS GSQESGSQPV
     TSGTAISSAS LVSSQASSSS FFTNANSYST TTTTSNMGIM NFTSSGSSGT SSQGQTSQRV
     GGLQGSDSLN IQQNQTSGGS LQGSQQKEGE QSQQTQQQQI LIQPQLVQGG QALQALQAAP
     LSGQTFTTQA ISQETLQNLQ LQAVQNSGPI IIRTPTVGPN GQVSWQTLQL QNLQVQNPQA
     QTITLAPMQG VSLGQTSSSN TTLTPIASAA SIPAGTVTVN AAQLSSMPGL QTINLSALGT
     SGIQVHQLPG LPLAIANTPG DHGAQLGLHG PGGDGIHDET AGGEEGENSP DPQPQAGRRT
     RREACTCPYC KDSEGRGSGD PGKKKQHICH IQGCGKVYGK TSHLRAHLRW HTGERPFMCN
     WSYCGKRFTR SDELQRHKRT HTGEKKFACP ECPKRFMRSD HLSKHIKTHQ NKKGGPGVAL
     SVGTLPLDSG AGSEGSGTAT PSALITTNMV AMEAICPEGI ARLANSGINV MQVTELQSIN
     ISGNGF
//
